About Us
Elan Corporation, plc is a biotechnology company, headquartered in Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan was incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. Elan shares trade on the New York and Irish Stock Exchanges.
JANSSEN Alzheimer Immunotherapy
Elan and Johnson & Johnson announced on September 17, 2009, that JANSSEN Alzheimer Immunotherapy, a Johnson & Johnson affiliate, had acquired substantially all of Elan’s assets related to the Alzheimer’s Immunotherapy Program (AIP) that Elan shared with Wyeth. Elan holds a 49.9% equity interest in JANSSEN Alzheimer Immunotherapy, and will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of AIP products.
JANSSEN Alzheimer Immunotherapy is continuing the AIP activities with Pfizer, which acquired Wyeth in 2009, to research, develop and commercialize selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. The program includes a number of compounds being evaluated for slowing the progression of Alzheimer's disease.
On August 6, 2012 Johnson & Johnson announced the discontinuation of Phase 3 development of bapineuzumab IV in mild to moderate Alzheimer's based on the co-primary clinical endpoints not being met. A subcutaneous formulation of bapineuzumab is in Phase 2 testing. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development. See www.clinicaltrials.gov for further details.
Marketed Products
Elan does not currently support any marketed products
TYSABRI®
Health care professionals and consumers with medical information inquiries, product complaints, or adverse event reports regarding TYSABRI® (natalizumab), please contact Biogen Idec at 1-866-MED-INFO (1-866-633-4636) or by e-mail at medinfo@biogenidec.com
Tysabri is marketed and distributed solely by Biogen Idec. Elan receives double digit tiered royalties on in-market sales.
Key Facts
LocationsDublin, Ireland (Headquarters)
Cambridge, Massachusetts
Zug, Switzerland
Employees: ~ 150 worldwide
Company Registration
Elan Corporation, plc
Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
Registered in Ireland
Registration Number 30356
Stock Exchange Listings
New York Stock Exchange (ELN)
Irish Stock Exchange
Investor Contacts
Chris Burns SVP, Global Investor Relations
Tel: 1-800-252-3526
Email: InvestorUS@elan.com
David Marshall PhD, VP, Global Investor Relations
Tel: 353-1-709-4444
Email: InvestorEurope@elan.com